SCHEMBL1842802

SCHEMBL1842802

Cc1sc2ccn(Cc3ccc(C(F)(F)F)cc3)c2c1C(=O)O

nearest known ligand 0.43

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
PTGER4 P35408 6/20 0.43
PTGDR Q13258 4/20 0.43
KDM4E B2RXH2 3/20 0.42
ALDH1A1 P00352 3/20 0.42
SMN1; SMN2 Q16637 1/20 0.42
PTGER2 P43116 3/20 0.41
TBXA2R P21731 1/20 0.41
PTGER1 P34995 1/20 0.41
PTGFR P43088 1/20 0.41
PTGER3 P43115 1/20 0.41
KCNQ3 O43525 2/20 0.40
KCNQ2 O43526 2/20 0.40
KCNQ4 P56696 2/20 0.40
KCNQ5 Q9NR82 2/20 0.40
P2RY14 Q15391 1/20 0.40
SRD5A2 P31213 1/20 0.37
NOTUM Q6P988 1/20 0.37
KCNH2 Q12809 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1845684 0.87 KDM4E (0.44) PTGER4PTGDRKDM4EALDH1A1SMN1; SMN2
SCHEMBL31613309 0.86 PTGER4 (0.43) PTGER4PTGDRKDM4EALDH1A1SMN1; SMN2
SCHEMBL27147548 0.86 KDM4E (0.43) PTGER4PTGDRKDM4EALDH1A1SMN1; SMN2
SCHEMBL27139680 0.85 KDM4E (0.42) PTGER4PTGDRKDM4EALDH1A1SMN1; SMN2
SCHEMBL24676590 0.84 NOTUM (0.36) PTGER4PTGDRKDM4EALDH1A1SMN1; SMN2
SCHEMBL1847633 0.83 PTGER4 (0.47) PTGER4PTGDRPTGER2TBXA2RPTGER1
SCHEMBL12549925 0.82 KDM4E (0.42) PTGER4PTGDRKDM4EALDH1A1SMN1; SMN2
SCHEMBL1847632 0.81 PTGER4 (0.66) PTGER4PTGDRPTGER2PTGER3
SCHEMBL1954049 0.81 PTGER4 (0.66) PTGER4PTGDRPTGER2PTGER3
SCHEMBL196448 0.80 PTGER4 (0.67) PTGER4PTGDRPTGER2TBXA2RPTGER1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260070918-A1 HETEROBICYCLIC COMPOUNDS AS EP4 RECEPTOR ANTAGONISTS SHENZHEN IONOVA LIFE SCIENCE CO., LTD. (CN) 2026-03-12 US disclosed
CN-120129685-A Heterobicyclic compounds as EP4 receptor antagonists 深圳市原力生命科学有限公司 2025-06-10 CN disclosed
US-12240860-B2 Heterobicyclic carboxylic acids and salts thereof Foshan Ionova Biotherapeutics Co., Inc. (CN) 2025-03-04 US disclosed
CN-111936502-B Heterobicyclic carboxylic acids and salts thereof 深圳市原力生命科学有限公司 2024-05-31 CN disclosed
US-20210079013-A1 Heterobicyclic Carboxylic Acids and Salts Thereof SHENZHEN IONOVA LIFE SCIENCE CO., LTD. (CN) 2021-03-18 US disclosed
CN-111936502-A Heterobicyclic carboxylic acids and salts thereof 深圳市原力生命科学有限公司 2020-11-13 CN disclosed
EP-2320906-B1 HETEROCYCLIC AMIDE DERIVATIVES AS EP4 RECEPTOR ANTAGONISTS BETA PHARMA CANADA INC (CA) 2016-02-24 EP disclosed
EP-2320906-B1 HETEROCYCLIC AMIDE DERIVATIVES AS EP4 RECEPTOR ANTAGONISTS BETA PHARMA CANADA INC (CA) 2016-02-24 EP disclosed
US-8404736-B2 Heterocyclic amide derivatives as EP4 receptor antagonists BETA PHARMA CANADA INC. (CA) 2013-03-26 US disclosed
US-8404736-B2 Heterocyclic amide derivatives as EP4 receptor antagonists BETA PHARMA CANADA INC. (CA) 2013-03-26 US disclosed
US-20110136887-A1 Heterocyclic Amide Derivatives as EP4 Receptor Antagonists BETA PHARMA CANADA INC. (CA) 2011-06-09 US disclosed
US-20110136887-A1 Heterocyclic Amide Derivatives as EP4 Receptor Antagonists BETA PHARMA CANADA INC. (CA) 2011-06-09 US disclosed
EP-2320906-A1 HETEROCYCLIC AMIDE DERIVATIVES AS EP4 RECEPTOR ANTAGONISTS Beta Pharma Canada Inc. (CA) 2011-05-18 EP disclosed
WO-2010019796-A1 HETEROCYCLIC AMIDE DERIVATIVES AS EP4 RECEPTOR ANTAGONISTS CHEMIETEK, LLC (US) 2010-02-18 WO disclosed
WO-2010019796-A1 HETEROCYCLIC AMIDE DERIVATIVES AS EP4 RECEPTOR ANTAGONISTS CHEMIETEK, LLC (US) 2010-02-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210079013-A1 Heterobicyclic Carboxylic Acids and Salts Thereof PTGER4, PTGER1, GPR4 PTGER4 1/4885PTGDR 24/4885KDM4E 2801/4885
US-20260070918-A1 HETEROBICYCLIC COMPOUNDS AS EP4 RECEPTOR ANTAGONISTS PTGER1, PTGER4, PTGER2 PTGER4 2/4885PTGDR 9/4885KDM4E 3741/4885
US-12240860-B2 Heterobicyclic carboxylic acids and salts thereof PTGER4, PTGER1, GPR4 PTGER4 1/4885PTGDR 24/4885KDM4E 2801/4885
US-20110136887-A1 Heterocyclic Amide Derivatives as EP4 Receptor Antagonists PTGER4, PTGER1, PTGER2 PTGER4 1/4885PTGDR 6/4885KDM4E 1395/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.